Therefore, in the present study, we performed a systematic exploration of PODNL1 through the Cancer Genome Atlas (TCGA) pan-cancer datasets, TIMER (Tumor Immune Estimation Resource), Gene Set Variation Analysis (GSVA), Gene Set Enrichment Analysis (GSEA), and the Cellminer, reconciling with the analyses of single-cell transcriptomes and immunotherapeutic cohorts in cancers, and validation by the tissue microarray (TMA)-based multiplex immunofluorescence staining in 20 types of cancer as well (Figure 1). This evidence concerns the gene PODNL1 and cancer.